Linked Life Data

2010632

Source:http://linkedlifedata.com/resource/pubmed/id/2010632

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1991-5-6
pubmed:abstractText
Group B streptococcal (GBS) infections cause significant morbidity and mortality in neonates and compromised hosts, who usually lack opsonic antibody to their infecting strain. Unfortunately, most conventional immunoglobulin preparations possess little GBS antibody. The protective activity of a human monoclonal antibody (HuMAb) and a human hyperimmune intravenous immunoglobulin (HivIg) were evaluated against these organisms and compared with a conventional intravenous immunoglobulin (ivIg). The HuMAb and the HivIg possessed significant protective activity (50%-95%) against extremely virulent strains of types I, II, and III GBS in doses as low as 4-20 mg/kg. In contrast, the conventional ivIg had little protective activity against some of these strains in doses as high as 500 mg/kg. The opsonic activity of the HuMAb and HivIg also usually exceeded that of the conventional ivIg. These studies suggest HivIg or HuMAb with markedly enhanced specific activity may provide optimal immunotherapy for GBS infections.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-1899
pubmed:author
pubmed:issnType
Print
pubmed:volume
163
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
792-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.
pubmed:affiliation
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City 84132.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't